Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1979 Nov;8(5):483–489. doi: 10.1111/j.1365-2125.1979.tb01031.x

The interaction of varying doses of dipyridamole and acetyl salicylic acid on the inhibition of platelet functions and their effect on bleeding time.

S M Rajah, A F Penny, M J Crow, M D Pepper, D A Watson
PMCID: PMC1429809  PMID: 508556

Abstract

1 In normal volunteers maximum reductions in platelet functions, collagen aggregation, adhesion and PF4 availability, were achieved using combined doses of 50 mg three times daily dipyridamole + 180 mg ASA or 75 mg three times daily dipyridamole + 120 mg ASA daily. 2 These doses did not prolong the bleeding time. 3 A synergistic effect has been demonstrated with 25 mg dipyridamole three times daily and 60 mg ASA. 4 At higher doses the effects on platelet functions were additive up to the maximal response. 5 The effect of low doses of ASA on platelet function was cumulative. 6 As lower doses of ASA in the combination studied inhibit platelet functions maximally without altering the bleeding time and probably without inhibiting prostacyclin, we suggest that these combinations of dipyridamole and ASA merit consideration in future clinical trials.

Full text

PDF
483

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BORN G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962 Jun 9;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
  2. Baenziger N. L., Dillender M. J., Majerus P. W. Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin. Biochem Biophys Res Commun. 1977 Sep 9;78(1):294–301. doi: 10.1016/0006-291x(77)91253-0. [DOI] [PubMed] [Google Scholar]
  3. Evans G., Packham M. A., Nishizawa E. E., Mustard J. F., Murphy E. A. The effect of acetylsalicyclic acid on platelet function. J Exp Med. 1968 Nov 1;128(5):877–894. doi: 10.1084/jem.128.5.877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Harker L. A., Slichter S. J. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med. 1970 Dec 10;283(24):1302–1305. doi: 10.1056/NEJM197012102832402. [DOI] [PubMed] [Google Scholar]
  6. Honour A. J., Hockaday T. D., Mann J. I. The synergistic effect of aspirin and dipyridamole upon platelet thrombi in living blood vessels. Br J Exp Pathol. 1977 Jun;58(3):268–272. [PMC free article] [PubMed] [Google Scholar]
  7. Kricheff I. I., Zucker M. B., Tschopp T. B., Kolodjiez A. Inhibition of thrombosis on vascular catheters in cats. Radiology. 1973 Jan;106(1):49–51. doi: 10.1148/106.1.49. [DOI] [PubMed] [Google Scholar]
  8. Metrication and medicine. Lancet. 1971 Feb 13;1(7694):339–341. [PubMed] [Google Scholar]
  9. Mielke C. H., Jr, Kaneshiro M. M., Maher I. A., Weiner J. M., Rapaport S. I. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood. 1969 Aug;34(2):204–215. [PubMed] [Google Scholar]
  10. Mills D. C., Smith J. B. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3':5'-cyclic monophosphate in platelets. Biochem J. 1971 Jan;121(2):185–196. doi: 10.1042/bj1210185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Moncada S., Higgs E. A., Vane J. R. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977 Jan 1;1(8001):18–20. doi: 10.1016/s0140-6736(77)91655-5. [DOI] [PubMed] [Google Scholar]
  12. Moncada S., Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet. 1978 Jun 17;1(8077):1286–1289. doi: 10.1016/s0140-6736(78)91269-2. [DOI] [PubMed] [Google Scholar]
  13. Niewiarowski S., Thomas D. P. Platelet factor 4 and adenosine diphosphate release during human platelet aggregation. Nature. 1969 Jun 28;222(5200):1269–1270. doi: 10.1038/2221269a0. [DOI] [PubMed] [Google Scholar]
  14. Rajah S. M., Crow M. J., Hamlin G. W., Kester R. C. Evaluation of the thrombo-resistant properties of arterial grafts in an artificial circulation. Thromb Res. 1978 Jan;12(1):141–151. doi: 10.1016/0049-3848(78)90092-0. [DOI] [PubMed] [Google Scholar]
  15. Rajah S. M., Crow M. J., Penny A. F., Ahmad R., Watson D. A. The effect of dipyridamole on platelet function: correlation with blood levels in man. Br J Clin Pharmacol. 1977 Apr;4(2):129–133. doi: 10.1111/j.1365-2125.1977.tb00683.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rome L. H., Lands W. E., Roth G. J., Majerus P. W. Aspirin as a quantitative acetylating reagent for the fatty acid oxygenase that forms prostaglandins. Prostaglandins. 1976 Jan;11(1):23–30. doi: 10.1016/0090-6980(76)90169-6. [DOI] [PubMed] [Google Scholar]
  17. Stuart R. K. Platelet function studies in human beings receiving 300 mg. of aspirin per day. J Lab Clin Med. 1970 Mar;75(3):463–471. [PubMed] [Google Scholar]
  18. TRINDER P. Rapid determination of salicylate in biological fluids. Biochem J. 1954 Jun;57(2):301–303. doi: 10.1042/bj0570301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tateson J. E., Moncada S., Vane J. R. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins. 1977 Mar;13(3):389–397. doi: 10.1016/0090-6980(77)90019-3. [DOI] [PubMed] [Google Scholar]
  20. Verstraete M. Are agents affecting platelet functions clinically useful? Am J Med. 1976 Dec;61(6):897–914. doi: 10.1016/0002-9343(76)90414-9. [DOI] [PubMed] [Google Scholar]
  21. Weiss H. J. Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis. Am Heart J. 1976 Jul;92(1):86–102. doi: 10.1016/s0002-8703(76)80408-5. [DOI] [PubMed] [Google Scholar]
  22. Willis A. L., Vane F. M., Kuhn D. C., Scott C. G., Petrin M. An endoperoxide aggregator (Lass), formed in platelets in response to thrombotic stimuli: purification, identification and unique biological significance. Prostaglandins. 1974 Dec 25;8(6):453–507. doi: 10.1016/0090-6980(74)90062-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES